Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.75
Bid: 18.00
Ask: 19.50
Change: 0.25 (1.35%)
Spread: 1.50 (8.333%)
Open: 18.50
High: 19.00
Low: 18.50
Prev. Close: 18.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Update

26 Mar 2012 07:00

RNS Number : 9988Z
Angle PLC
26 March 2012
 



For immediate release

26 March 2012

 

ANGLE plc

 

("ANGLE" or the "Company")

 

GEOMERICS EXPANDS PRODUCT RANGE AND SALES

 

 

ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce positive progress in new products, sales and market recognition at its 33%-owned portfolio company Geomerics, which specialises in computer games middleware.

 

At the recent Game Developers Conference (GDC 2012) in San Francisco, Geomerics announced the development of new products for mobile devices and for Nintendo's new Wii™ U console. These new products significantly expand the addressable market for Geomerics products.

 

The company demonstrated a range of new technologies aimed at rounding out the Enlighten offering and getting 'next gen ready'. In partnership with ARM, they showcased Enlighten running smoothly on a Mali-based Samsung Galaxy Tab 7.7 tablet on the expo floor. This is an expansion of Geomerics' product capability and Enlighten, via ARM CPU, now supports a wide range of mobile devices including the iOS-based iPad and iPhone, Android devices and PlayStation® Vita, offering new sales opportunities.

 

Geomerics also announced its new product capability for Nintendo's new Wii™ U console, the successor to the highly successful Wii™ adding to its capability on the PC, PS3 and Xbox360. Geomerics also displayed on the NVIDIA and Intel booths at GDC 2012, reaffirming their commitment to high-end gaming experiences on the PC and console.

 

Geomerics sales continue to strengthen. Since GDC 2012 finished on 9th March, Geomerics has already been notified of four new sales for major new games, three of which are to entirely new customers, and its pipeline of prospective customers is steadily increasing.

 

Finally, there has been further market recognition for Geomerics' Enlighten with a BAFTA award being won by a computer game incorporating the Enlighten lighting solution.

 

The British Academy of Film and Television Arts (BAFTA) 2011 GAME Award has been awarded to Battlefield 3, an Electronic Arts game incorporating Enlighten. The GAME Award recognises the best game of the year, and is the only category at the British Academy Video Games Awards to be voted for by the general public.

 

Battlefield 3 is the fastest selling Electronic Arts game ever, selling more than 5 million units in its first week of release. Enlighten is the only real-time global illumination solution available for computer games, enabling the lighting to be realistically calculated in real-time as the player interacts with the game environment and other players. As a result, Enlighten provides a much more realistic player experience.

 

The reviews of Battlefield 3 have frequently singled out the lighting. For example The Guardian reported "Visually Battlefield 3 is a marvel of beautiful lighting effects" and GameSpy in its review said "Once they see the light - they'll understand what a special game Battlefield 3 is". The quality of the lighting and graphics in general has been a major contributor to the success of the game.

 

In a first time win at the BAFTA awards for the Battlefield franchise, it beat titles including FIFA 12, The Elder Scrolls V: Skyrim and Batman: Arkham City. Also, for the first time Battlefield beat the long-standing favourite Call of Duty, which has dominated the GAME Award for the past three years.

 

 

Gary Lewis, Chief Executive of Geomerics, commented:

"The BAFTA award for Battlefield 3 is an excellent further endorsement of the success of the game. We are pleased with ongoing adoption of the Enlighten technology in major new games. 2012 looks like being a great year for us and the expansion into mobile computing offers substantial growth potential for the future."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are delighted by Geomerics' ongoing success and believe the company is positioned well for the future."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

0207 653 0030

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQXLFLLXFFBBL
Date   Source Headline
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.